Protagonist Therapeutics, Inc.PTGXNASDAQ
Loading
Year-over-year net income growth rate
Percentile
P44
Within normal range
vs 2Y Ago
-0.1x
Contraction
Streak
2 qtr
Consecutive growthDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -12.82% |
| Q3 2025 | -13.14% |
| Q2 2025 | -198.34% |
| Q1 2025 | -108.85% |
| Q4 2024 | 496.49% |
| Q3 2024 | -8.47% |
| Q2 2024 | -114.77% |
| Q1 2024 | 658.51% |
| Q4 2023 | 180.15% |
| Q3 2023 | 11.32% |
| Q2 2023 | -14.04% |
| Q1 2023 | 1.37% |
| Q4 2022 | -9.48% |
| Q3 2022 | 23.89% |
| Q2 2022 | -96.07% |
| Q1 2022 | 43.29% |
| Q4 2021 | -9.18% |
| Q3 2021 | -9.60% |
| Q2 2021 | -28.52% |
| Q1 2021 | -27.07% |
| Q4 2020 | -143.28% |
| Q3 2020 | 60.03% |
| Q2 2020 | 3.28% |
| Q1 2020 | -14.74% |
| Q4 2019 | -6.65% |
| Q3 2019 | 43.75% |
| Q2 2019 | -106.86% |
| Q1 2019 | -1.72% |
| Q4 2018 | -58.73% |
| Q3 2018 | -0.83% |
| Q2 2018 | -13.08% |
| Q1 2018 | -151.02% |
| Q4 2017 | 36.75% |
| Q3 2017 | 67.79% |
| Q2 2017 | -6.23% |
| Q1 2017 | -25.36% |
| Q4 2016 | -58.78% |
| Q3 2016 | 0.20% |
| Q2 2016 | 39.58% |
| Q1 2016 | -113.85% |